<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-11-21T23:36:06+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://news.medxy.ai/zh/ethical-dilemmas-prenatal-testing/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T05:00:27-08:00</news:publication_date><news:title>产前检测的伦理抉择：成年期起病遗传性疾病中的两难与思考</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/ethical-dilemmas-prenatal-testing-huntington-disease/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T05:00:00-08:00</news:publication_date><news:title>出生前検査における倫理的選択：成人発症の遺伝性疾患に見られるジレンマと考察</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/ethical-dilemmas-prenatal-testing-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:59:32-08:00</news:publication_date><news:title>Các lựa chọn đạo đức trong xét nghiệm trước sinh đối với bệnh Huntington: Những tình huống tiến thoái lưỡng nan và suy ngẫm về các rối loạn di truyền khởi phát ở tuổi trưởng thành</news:title></news:news></url>
<url><loc>https://news.medxy.ai/navigating-the-ethical-crossroads-of-prenatal-testing-for-adult-onset-genetic-conditions-the-case-of-huntington-disease/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:59:08-08:00</news:publication_date><news:title>Navigating the Ethical Crossroads of Prenatal Testing for Adult-Onset Genetic Conditions: The Case of Huntington Disease</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/genetic-biomarkers-giant-cell-arteritis/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:58:28-08:00</news:publication_date><news:title>遗传生物标志物揭示巨细胞动脉炎的不同临床亚组：诊断与个体化管理的新启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/genetic-biomarkers-giant-cell-arteritis-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:58:07-08:00</news:publication_date><news:title>巨細胞性動脈炎の臨床サブグループを規定する遺伝学的バイオマーカー：診断と個別化管理への示唆</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/genetic-biomarkers-giant-cell-arteritis-3/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:57:44-08:00</news:publication_date><news:title>Các dấu ấn sinh học di truyền tiết lộ những phân nhóm lâm sàng riêng biệt của bệnh viêm động mạch tế bào khổng lồ: Những hiểu biết mới phục vụ chẩn đoán và quản lý cá thể hóa</news:title></news:news></url>
<url><loc>https://news.medxy.ai/genetic-biomarkers-define-distinct-clinical-subgroups-in-giant-cell-arteritis-implications-for-diagnosis-and-personalized-management/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:57:22-08:00</news:publication_date><news:title>Genetic Biomarkers Define Distinct Clinical Subgroups in Giant Cell Arteritis: Implications for Diagnosis and Personalized Management</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/clad-monitoring-with-alveolar-nitric-oxide/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:56:44-08:00</news:publication_date><news:title>CLAD监测新思路：将肺泡一氧化氮纳入肺移植随访评估</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/refining-clad-surveillance/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:56:23-08:00</news:publication_date><news:title>CLADサーベイランスを磨く：肺胞一酸化窒素を組み込んだ新たな肺移植モニタリング</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/clad-monitoring-upgrade/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:56:00-08:00</news:publication_date><news:title>Nâng cấp giám sát CLAD: Tích hợp nitric oxide phế nang để theo dõi ghép phổi hiệu quả hơn</news:title></news:news></url>
<url><loc>https://news.medxy.ai/refining-clad-surveillance-integrating-alveolar-nitric-oxide-for-enhanced-lung-transplant-monitoring/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:55:42-08:00</news:publication_date><news:title>Refining CLAD Surveillance: Integrating Alveolar Nitric Oxide for Enhanced Lung Transplant Monitoring</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/cancer-risk-scleroderma/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:55:05-08:00</news:publication_date><news:title>局限性硬皮病与系统性硬化症的癌症风险各异：一项大型人群队列研究的新发现</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/cancer-risk-scleroderma-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:54:46-08:00</news:publication_date><news:title>限局性強皮症と全身性強皮症にみられる異なるがんリスク：大規模集団ベースコホート研究からの知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/cancer-risk-scleroderma-and-ss/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:54:24-08:00</news:publication_date><news:title>Sự khác biệt về nguy cơ ung thư giữa bệnh xơ cứng bì khu trú và bệnh xơ cứng bì hệ thống: Những phát hiện mới từ một nghiên cứu đoàn hệ quy mô lớn dựa trên quần thể</news:title></news:news></url>
<url><loc>https://news.medxy.ai/distinct-cancer-risks-in-morphea-and-systemic-sclerosis-insights-from-a-large-population-based-cohort-study/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:54:04-08:00</news:publication_date><news:title>Distinct Cancer Risks in Morphea and Systemic Sclerosis: Insights from a Large Population-Based Cohort Study</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/optimizing-lymphaticovenous-anastomosis/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:53:26-08:00</news:publication_date><news:title>优化淋巴静脉吻合：影响淋巴水肿手术疗效的关键术中因素</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/optimizing-lymphaticovenous-anastomosis-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:53:08-08:00</news:publication_date><news:title>リンパ管静脈吻合術の最適化：リンパ浮腫手術の治療成績に影響を及ぼす術中の重要な要因</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/optimizing-lymphatic-venous-anastomosis/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:52:45-08:00</news:publication_date><news:title>Tối ưu hóa nối bạch huyết-tĩnh mạch: Những yếu tố trong mổ quyết định kết quả tốt hơn trong phẫu thuật phù bạch huyết</news:title></news:news></url>
<url><loc>https://news.medxy.ai/refining-lymphovenous-anastomosis-intraoperative-factors-driving-improved-outcomes-in-lymphedema-surgery/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:52:26-08:00</news:publication_date><news:title>Refining Lymphovenous Anastomosis: Intraoperative Factors Driving Improved Outcomes in Lymphedema Surgery</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/university-mental-health-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:51:47-08:00</news:publication_date><news:title>AI时代的大学心理健康转型：从危机应对到整合式照护</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/university-mental-health-reform/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:51:27-08:00</news:publication_date><news:title>AI時代の大学メンタルヘルス改革：危機対応から統合ケアへ</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/university-mental-health-ai-era/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:51:05-08:00</news:publication_date><news:title>Chuyển đổi sức khỏe tâm thần đại học trong kỷ nguyên AI: Từ khủng hoảng đến chăm sóc tích hợp</news:title></news:news></url>
<url><loc>https://news.medxy.ai/transforming-university-mental-health-in-the-ai-era-from-crisis-to-integrated-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:50:45-08:00</news:publication_date><news:title>Transforming University Mental Health in the AI Era: From Crisis to Integrated Care</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/news-2-triggered-sepsis-bundle/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:50:08-08:00</news:publication_date><news:title>NEWS-2 触发的急诊脓毒症 Hour-1 方案：来自 NEWS-1 TRIPS 试点试验的启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/news-2-sepsis-bundle/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:49:48-08:00</news:publication_date><news:title>救急部門におけるNEWS-2起動型Hour-1敗血症バンドルの評価：NEWS-1 TRIPSパイロット試験からの知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/news-2-sepsis-intervention/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:49:10-08:00</news:publication_date><news:title>NEWS-2 có thực sự hữu ích để kích hoạt gói can thiệp sepsis giờ đầu tại khoa cấp cứu? Bằng chứng ban đầu từ thử nghiệm thí điểm NEWS-1 TRIPS</news:title></news:news></url>
<url><loc>https://news.medxy.ai/evaluating-news-2-guided-hour-1-sepsis-bundle-in-emergency-departments-insights-from-the-news-1-trips-pilot-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:48:49-08:00</news:publication_date><news:title>Evaluating NEWS-2 Guided Hour-1 Sepsis Bundle in Emergency Departments: Insights from the NEWS-1 TRIPS Pilot Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/ember-trial-veteran-weight-management-feedback/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:48:09-08:00</news:publication_date><news:title>EMBER試験：退役軍人の体重管理参加を促進する自主学習型動機づけツールのハイブリッド第1種ランダム化臨床試験</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/ember-trial-veteran-weight-management/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:47:50-08:00</news:publication_date><news:title>Thử nghiệm EMBER: Thử nghiệm lâm sàng ngẫu nhiên hỗn hợp loại 1 về công cụ tạo động lực tự hướng dẫn nhằm thu hút cựu chiến binh tham gia quản lý cân nặng</news:title></news:news></url>
<url><loc>https://news.medxy.ai/the-ember-trial-a-hybrid-type-1-randomized-clinical-trial-of-a-self-guided-motivational-tool-to-engage-veterans-in-weight-management/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:47:32-08:00</news:publication_date><news:title>The EMBER Trial: A Hybrid Type 1 Randomized Clinical Trial of a Self-Guided Motivational Tool to Engage Veterans in Weight Management</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/nur77-regulates-diabetic-anemia/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:46:57-08:00</news:publication_date><news:title>Nur77：通过造血谱系调控阻止糖尿病贫血的关键分子</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/nur77-prevents-diabetic-anemia/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:46:36-08:00</news:publication_date><news:title>Nur77による造血系統制御が糖尿病性貧血を防ぐ鍵となる</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/nur77-diabetic-anemia-regulator/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:46:15-08:00</news:publication_date><news:title>Nur77: Bộ điều hòa then chốt giúp ngăn ngừa thiếu máu do đái tháo đường thông qua kiểm soát dòng tạo máu</news:title></news:news></url>
<url><loc>https://news.medxy.ai/nur77-a-key-regulator-preventing-diabetic-anemia-through-hematopoietic-lineage-control/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:45:56-08:00</news:publication_date><news:title>Nur77: A Key Regulator Preventing Diabetic Anemia Through Hematopoietic Lineage Control</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/sepsis-time-zero-criteria/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:45:20-08:00</news:publication_date><news:title>重塑脓毒症“time zero”：找出影响抗生素给药时机与死亡结局的器官功能障碍标准</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/revisiting-sepsis-time-zero/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:44:58-08:00</news:publication_date><news:title>敗血症の「time zero」を見直す：抗菌薬投与時期と死亡転帰に影響する臓器障害基準の特定</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/sepsis-time-zero-criteria-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:44:33-08:00</news:publication_date><news:title>Tinh chỉnh “time zero” của sepsis: xác định các tiêu chí rối loạn chức năng cơ quan ảnh hưởng đến thời điểm kháng sinh và kết cục tử vong</news:title></news:news></url>
<url><loc>https://news.medxy.ai/refining-sepsis-time-zero-identifying-organ-dysfunction-criteria-that-impact-antibiotic-timing-and-mortality-outcomes/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:44:08-08:00</news:publication_date><news:title>Refining Sepsis Time Zero: Identifying Organ Dysfunction Criteria that Impact Antibiotic Timing and Mortality Outcomes</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/faricimab-diabetic-macular-edema-4-year-results/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:43:29-08:00</news:publication_date><news:title>Faricimab 治疗糖尿病黄斑水肿的 4 年疗效：来自 RHONE-X 扩展研究及相关证据的启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/faricimab-diabetic-macular-edema-four-year-results/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:43:07-08:00</news:publication_date><news:title>糖尿病黄斑浮腫に対するFaricimabの4年成績：RHONE-X延長試験と関連エビデンスからの示唆</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/faricimab-diabetic-macular-edema-four-year-results-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:42:42-08:00</news:publication_date><news:title>Kết quả 4 năm sử dụng Faricimab cho bệnh phù hoàng điểm do đái tháo đường: Những gợi ý từ nghiên cứu mở rộng RHONE-X và các bằng chứng liên quan</news:title></news:news></url>
<url><loc>https://news.medxy.ai/four-year-outcomes-of-faricimab-in-diabetic-macular-edema-insights-from-the-rhone-x-extension-trial-and-related-evidence/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:42:22-08:00</news:publication_date><news:title>Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Insights from the RHONE-X Extension Trial and Related Evidence</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/dacryocystorhinostomy-efficacy-comparison/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:41:27-08:00</news:publication_date><news:title>外路与动力辅助内镜下泪囊鼻腔造口术联合丝裂霉素C治疗鼻泪管阻塞的疗效比较：一项随机对照试验</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/dacryocystorhinostomy-efficacy-comparison-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:41:05-08:00</news:publication_date><news:title>鼻涙管閉塞に対するマイトマイシンC併用・外切開法および動力補助内視鏡下涙嚢鼻腔吻合術の治療成績の比較：ランダム化比較試験</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/dacryocystorhinostomy-comparison/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:40:43-08:00</news:publication_date><news:title>So sánh kết quả phẫu thuật nối thông túi lệ &#8211; mũi qua đường ngoài và nội soi có hỗ trợ dụng cụ tạo lực kèm Mitomycin C trong tắc ống lệ mũi: thử nghiệm ngẫu nhiên có đối chứng</news:title></news:news></url>
<url><loc>https://news.medxy.ai/comparative-outcomes-of-external-versus-powered-endoscopic-dacryocystorhinostomy-with-mitomycin-c-in-nasolacrimal-duct-obstruction-a-randomized-controlled-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:40:22-08:00</news:publication_date><news:title>Comparative Outcomes of External versus Powered Endoscopic Dacryocystorhinostomy with Mitomycin C in Nasolacrimal Duct Obstruction: A Randomized Controlled Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/late-preterm-steroid-practice-variation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:39:44-08:00</news:publication_date><news:title>晚期早产产前糖皮质激素使用的医院差异：美国实践不均衡的揭示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/late-preterm-steroid-practice-variation-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:39:20-08:00</news:publication_date><news:title>後期早産における出生前糖質コルチコイド使用の施設間差：米国の診療における不均衡の露呈</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/antenatal-corticosteroids-late-preterm/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:38:55-08:00</news:publication_date><news:title>Sử dụng corticosteroid trước sinh cho sinh non muộn: Sự khác biệt giữa các bệnh viện tại Hoa Kỳ</news:title></news:news></url>
<url><loc>https://news.medxy.ai/hospital-level-variation-in-antenatal-corticosteroid-use-for-late-preterm-births-unveiling-practice-disparities-in-the-united-states/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:38:33-08:00</news:publication_date><news:title>Hospital-Level Variation in Antenatal Corticosteroid Use for Late Preterm Births: Unveiling Practice Disparities in the United States</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/par2-ibuprofen-pain-ibd-itching/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:37:53-08:00</news:publication_date><news:title>PAR2内体信号放大IBS组胺致痛：机制解析与临床启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/par2-signaling-amplifies-pain/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:37:32-08:00</news:publication_date><news:title>エンドソームで続くPAR2シグナルが、過敏性腸症候群のヒスタミン誘発痛を増幅する：機序と臨床的意義</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/protease-activated-receptor-2-pain/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:37:08-08:00</news:publication_date><news:title>Tín hiệu thể nội bào của thụ thể hoạt hóa bởi protease-2 khuếch đại đau do histamine trong hội chứng ruột kích thích: Những hiểu biết cơ chế và ý nghĩa lâm sàng</news:title></news:news></url>
<url><loc>https://news.medxy.ai/endosomal-signalling-of-protease-activated-receptor-2-amplifies-histamine-induced-pain-in-irritable-bowel-syndrome-mechanistic-insights-and-clinical-implications/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:36:47-08:00</news:publication_date><news:title>Endosomal Signalling of Protease-Activated Receptor-2 Amplifies Histamine-Induced Pain in Irritable Bowel Syndrome: Mechanistic Insights and Clinical Implications</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/mivocabtagene-stiff-person-syndrome/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:36:02-08:00</news:publication_date><news:title>Mivocabtagene Autoleucel用于僵人综合征的CD19 CAR T细胞治疗：疗效、安全性及新兴临床范式</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/mivocabtagene-car-t-in-stiff-person-syndrome/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:35:43-08:00</news:publication_date><news:title>僵人综合征中的Mivocabtagene Autoleucel CD19 CAR T细胞治疗：疗效、安全性与新兴临床范式</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/mivocabtagene-autoleucel-in-stiff-person-syndrome/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:35:19-08:00</news:publication_date><news:title>Mivocabtagene Autoleucel: Bước tiến mới của liệu pháp tế bào T CAR CD19 trong hội chứng người cứng</news:title></news:news></url>
<url><loc>https://news.medxy.ai/mivocabtagene-autoleucel-cd19-car-t-cell-therapy-in-stiff-person-syndrome-efficacy-safety-and-emerging-clinical-paradigm/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:35:00-08:00</news:publication_date><news:title>Mivocabtagene Autoleucel CD19 CAR T-Cell Therapy in Stiff Person Syndrome: Efficacy, Safety, and Emerging Clinical Paradigm</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/refractory-autoimmune-hypophysitis-management/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:34:13-08:00</news:publication_date><news:title>难治性原发性自身免疫性垂体炎如何识别与管理？——回顾性队列研究带来的启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/diagnosing-treating-autoimmune-hypophysitis/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:33:53-08:00</news:publication_date><news:title>難治性原発性自己免疫性下垂体炎をどう診断し、どう治療するか：後ろ向きコホート研究からの示唆</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/refractory-autoimmune-hypophysitis/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:33:29-08:00</news:publication_date><news:title>Viêm tuyến yên tự miễn nguyên phát kháng trị: nhận diện sớm và chiến lược xử trí từ nghiên cứu đoàn hệ hồi cứu</news:title></news:news></url>
<url><loc>https://news.medxy.ai/defining-and-managing-refractory-primary-autoimmune-hypophysitis-insights-from-a-retrospective-cohort-study/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:33:18-08:00</news:publication_date><news:title>Defining and Managing Refractory Primary Autoimmune Hypophysitis: Insights from a Retrospective Cohort Study</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/ischemic-heart-disease-treatment/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:32:43-08:00</news:publication_date><news:title>晚期慢性肾脏病合并稳定性冠状动脉疾病：侵入性治疗还是保守治疗更有利？——来自 ISCHEMIA-CKD EXTEND 的长期结局</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/long-term-outcomes-ischemia-ckd/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:32:23-08:00</news:publication_date><news:title>進行したCKDを伴う安定冠動脈疾患における侵襲的管理と保存的管理の長期転帰：ISCHEMIA-CKD EXTENDからの知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/long-term-outcomes-in-advanced-ckd/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:31:59-08:00</news:publication_date><news:title>Kết cục dài hạn giữa chiến lược xâm lấn và bảo tồn ở bệnh động mạch vành ổn định kèm CKD tiến triển: dữ liệu từ ISCHEMIA-CKD EXTEND</news:title></news:news></url>
<url><loc>https://news.medxy.ai/long-term-outcomes-of-invasive-versus-conservative-management-in-stable-coronary-disease-with-advanced-ckd-insights-from-ischemia-ckd-extend/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:31:38-08:00</news:publication_date><news:title>Long-Term Outcomes of Invasive Versus Conservative Management in Stable Coronary Disease with Advanced CKD: Insights from ISCHEMIA-CKD EXTEND</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/low-muscle-power-mortality-risk/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:31:01-08:00</news:publication_date><news:title>血液透析患者低肌肉机械功率能否预示死亡风险？——来自SARC-HD队列的研究启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/low-muscle-power-mortality/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:30:41-08:00</news:publication_date><news:title>血液透析患者の死亡予測因子としての低筋機械的パワー：SARC-HDコホートからの知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/low-mechanical-power-predicts-mortality/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:30:17-08:00</news:publication_date><news:title>Công suất cơ học cơ thấp có dự báo tử vong ở bệnh nhân chạy thận nhân tạo không? Bằng chứng từ đoàn hệ SARC-HD</news:title></news:news></url>
<url><loc>https://news.medxy.ai/low-muscle-mechanical-power-as-a-predictor-of-mortality-in-hemodialysis-patients-insights-from-the-sarc-hd-cohort/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:29:58-08:00</news:publication_date><news:title>Low Muscle Mechanical Power as a Predictor of Mortality in Hemodialysis Patients: Insights from the SARC-HD Cohort</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/physiological-effects-exercise-training/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:29:18-08:00</news:publication_date><news:title>早期心脏康复中低容量高强度间歇训练与中等强度持续训练的生理效应比较</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/physiological-effects-exercise-training-hiit/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:28:58-08:00</news:publication_date><news:title>心臓リハビリテーション早期における低容量高強度インターバルトレーニングと中等強度持続的トレーニングの比較</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/physiological-effects-hiit-exercise-training/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:28:34-08:00</news:publication_date><news:title>So sánh tác động của tập luyện ngắt quãng cường độ cao với khối lượng thấp và tập luyện liên tục cường độ trung bình trong giai đoạn đầu phục hồi chức năng tim</news:title></news:news></url>
<url><loc>https://news.medxy.ai/comparative-physiological-impacts-of-low-volume-high-intensity-interval-training-versus-moderate-intensity-continuous-training-in-early-cardiac-rehabilitation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:28:14-08:00</news:publication_date><news:title>Comparative Physiological Impacts of Low-Volume High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Early Cardiac Rehabilitation</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/implant-bone-stability-11-years-outcome/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:27:33-08:00</news:publication_date><news:title>种植体周围边缘骨能否长期保持稳定？——数字化与传统修复方案的对比研究（随访期长达11.6年）</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/implant-bone-stability/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:27:09-08:00</news:publication_date><news:title>インプラント周囲辺縁骨は長期に安定するか：デジタルと従来法の補綴アプローチを11.6年まで比較</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/implant-bone-stability-over-11-years-outcome/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:26:44-08:00</news:publication_date><news:title>Xương viền quanh implant có ổn định lâu dài không: So sánh các phương pháp phục hình kỹ thuật số và truyền thống trong thời gian theo dõi lên đến 11,6 năm</news:title></news:news></url>
<url><loc>https://news.medxy.ai/long-term-stability-of-peri-implant-crestal-bone-comparative-insights-between-digital-and-conventional-restorative-approaches-over-up-to-11-6-years/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:26:26-08:00</news:publication_date><news:title>Long-Term Stability of Peri-Implant Crestal Bone: Comparative Insights Between Digital and Conventional Restorative Approaches Over Up to 11.6 Years</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/venous-thrombosis-prevention/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-21T04:25:47-08:00</news:publication_date><news:title>髋膝关节置换术后静脉血栓栓塞预防：阿司匹林、华法林与利伐沙班的比较</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/vte-prevention-after-joint-replacement/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-21T04:25:25-08:00</news:publication_date><news:title>人工股関節・膝関節置換術後のVTE予防：アスピリン、ワルファリン、リバーロキサバンを比較</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/aspirin-warfarin-rivaroxaban-thrombosis-prevention/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-21T04:24:59-08:00</news:publication_date><news:title>Aspirin, warfarin và rivaroxaban: thuốc nào tối ưu để phòng ngừa huyết khối tĩnh mạch thuyên tắc sau thay khớp háng hoặc khớp gối?</news:title></news:news></url>
<url><loc>https://news.medxy.ai/comparing-aspirin-warfarin-and-rivaroxaban-for-preventing-venous-thromboembolism-after-hip-or-knee-replacement/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T04:24:39-08:00</news:publication_date><news:title>Comparing Aspirin, Warfarin, and Rivaroxaban for Preventing Venous Thromboembolism After Hip or Knee Replacement</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ai-riemann-debate/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T08:27:00-08:00</news:publication_date><news:title>AI-Assisted Riemann Hypothesis Claim Sparks Debate Over Verification—and Signals a Broader &#8220;AI Moment&#8221; for Science</news:title></news:news></url>
<url><loc>https://news.medxy.ai/1-5-kg-emerges-as-a-key-risk-threshold-in-transcatheter-pda-closure-for-small-infants/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T08:21:00-08:00</news:publication_date><news:title>1.5 kg Emerges as a Key Risk Threshold in Transcatheter PDA Closure for Small Infants</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/digital-parenting-prevents-child-abuse/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:54:37-08:00</news:publication_date><news:title>数字化养育如何助力减少儿童性暴力与受虐待：来自坦桑尼亚大型试验的证据</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/reducing-child-abuse/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:54:18-08:00</news:publication_date><news:title>デジタル子育てで児童の性暴力と虐待を減らす：タンザニア大規模試験からのエビデンス</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/digital-parenting-child-protection/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:53:57-08:00</news:publication_date><news:title>Nuôi dạy con cái số để giảm bạo lực tình dục và ngược đãi trẻ em: Bằng chứng từ một thử nghiệm quy mô lớn tại Tanzania</news:title></news:news></url>
<url><loc>https://news.medxy.ai/harnessing-digital-parenting-to-reduce-childhood-sexual-violence-and-maltreatment-evidence-from-a-large-scale-tanzanian-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:53:41-08:00</news:publication_date><news:title>Harnessing Digital Parenting to Reduce Childhood Sexual Violence and Maltreatment: Evidence from a Large-scale Tanzanian Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/investing-in-child-primary-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:53:01-08:00</news:publication_date><news:title>将儿童纳入初级保健投资：不容忽视的关键议题</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/prioritize-children-primary-care-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:52:44-08:00</news:publication_date><news:title>プライマリ・ケアへの投資に子どもを含めること：看過できない重要な課題</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/prioritize-children-primary-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:52:24-08:00</news:publication_date><news:title>Đưa trẻ em vào trọng tâm của cuộc thảo luận đầu tư cho chăm sóc ban đầu</news:title></news:news></url>
<url><loc>https://news.medxy.ai/integrating-children-into-the-primary-care-investment-conversation-a-critical-imperative/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:52:09-08:00</news:publication_date><news:title>Integrating Children into the Primary Care Investment Conversation: A Critical Imperative</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/fcrn-targeting-scleroderma/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:51:25-08:00</news:publication_date><news:title>靶向FcRn对抗系统性硬化症：Efgartigimod带来的临床前新进展</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/efgartigimod-scleroderma/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:51:05-08:00</news:publication_date><news:title>FcRnを標的に全身性強皮症へ挑む：efgartigimodが示した有望な前臨床成果</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/targeting-fcrn-scleroderma/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:50:42-08:00</news:publication_date><news:title>Nhắm đích FcRn để đối phó xơ cứng bì hệ thống: tiến bộ tiền lâm sàng đầy hứa hẹn với Efgartigimod</news:title></news:news></url>
<url><loc>https://news.medxy.ai/targeting-fcrn-to-combat-systemic-sclerosis-promising-preclinical-advances-with-efgartigimod/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:50:24-08:00</news:publication_date><news:title>Targeting FcRn to Combat Systemic Sclerosis: Promising Preclinical Advances with Efgartigimod</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/alcohol-abstinence-period-liver-transplantation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:49:37-08:00</news:publication_date><news:title>重新审视强制戒酒期：对酒精相关肝病肝移植结局的影响</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/rethinking-abstinence-requirements/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:49:20-08:00</news:publication_date><news:title>6か月断酒要件の再考：アルコール関連肝疾患における肝移植成績への影響</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/mandatory-abstinence-liver-transplantation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:49:01-08:00</news:publication_date><news:title>Xem xét lại thời gian cai rượu bắt buộc: Tác động đến kết cục ghép gan ở bệnh gan liên quan đến rượu</news:title></news:news></url>
<url><loc>https://news.medxy.ai/reevaluating-mandatory-sobriety-periods-impact-on-liver-transplant-outcomes-in-alcohol-associated-liver-disease/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:48:46-08:00</news:publication_date><news:title>Reevaluating Mandatory Sobriety Periods: Impact on Liver Transplant Outcomes in Alcohol-Associated Liver Disease</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/relabotulinumtoxina-frown-lines/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:42:16-08:00</news:publication_date><news:title>液体 RelabotulinumtoxinA 治疗眉间纹的长期美容疗效与安全性：一项12个月随机对照试验</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/long-term-relabotulinumtoxina-a-safety/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:41:59-08:00</news:publication_date><news:title>眉間ジワ治療における液状RelabotulinumtoxinAの長期的な美容効果と安全性：12カ月間の無作為化比較試験</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/long-term-relabotulinumtoxina-safety/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:41:40-08:00</news:publication_date><news:title>Hiệu quả thẩm mỹ bền vững và độ an toàn dài hạn của RelabotulinumtoxinA dạng lỏng trong điều trị nếp nhăn gian mày: Thử nghiệm ngẫu nhiên có đối chứng kéo dài 12 tháng</news:title></news:news></url>
<url><loc>https://news.medxy.ai/long-term-aesthetic-efficacy-and-safety-of-liquid-relabotulinumtoxina-for-glabellar-lines-a-12-month-randomized-controlled-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:41:26-08:00</news:publication_date><news:title>Long-Term Aesthetic Efficacy and Safety of Liquid RelabotulinumtoxinA for Glabellar Lines: A 12-Month Randomized Controlled Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/talking-with-voices-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:40:42-08:00</news:publication_date><news:title>与常规治疗相比，对话式“与声音对话”治疗能否改善持续性痛苦性听幻觉成人的结局？——来自英国 Talking with Voices-II 随机对照试验的证据</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/talking-with-voices-trial-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:40:22-08:00</news:publication_date><news:title>通常の治療と比較して、対話型治療は、持続的で苦痛を伴う幻聴がある成人の転帰を改善できるか？</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/talking-with-voices-trial-3/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:40:01-08:00</news:publication_date><news:title>So với phương pháp chăm sóc thông thường, liệu liệu pháp trò chuyện có thể cải thiện kết quả cho người trưởng thành đang trải qua các ảo thanh dai dẳng gây khó chịu hay không?</news:title></news:news></url>
<url><loc>https://news.medxy.ai/dialogical-therapy-plus-treatment-as-usual-versus-treatment-as-usual-in-adults-with-distressing-and-persistent-auditory-hallucinations-evidence/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:39:44-08:00</news:publication_date><news:title>Dialogical Therapy Plus Treatment as Usual Versus Treatment as Usual in Adults with Distressing and Persistent Auditory Hallucinations: Evidence from the UK Talking with Voices-II Randomised Controlled Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/pediatric-icu-insights/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:38:47-08:00</news:publication_date><news:title>儿科紧急ICU会诊：EPOCH试验带来的关键启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/emergency-pediatric-icu-consultation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:38:28-08:00</news:publication_date><news:title>小児診療における緊急ICUコンサルテーション：EPOCH試験から得られた知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/emergency-pediatric-icu-consultation-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:38:01-08:00</news:publication_date><news:title>Tư vấn ICU khẩn cấp trong chăm sóc nhi khoa: Góc nhìn từ thử nghiệm EPOCH</news:title></news:news></url>
<url><loc>https://news.medxy.ai/urgent-icu-consultations-in-pediatric-care-insights-from-the-epoch-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:37:45-08:00</news:publication_date><news:title>Urgent ICU Consultations in Pediatric Care: Insights from the EPOCH Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/healthcare-social-needs/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:37:05-08:00</news:publication_date><news:title>大型医疗系统中的健康相关社会需求：整合 CMS 强制与扩展领域，推动患者全方位照护</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/social-health-needs-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:36:44-08:00</news:publication_date><news:title>大規模医療システムにおける健康関連社会的ニーズ：CMS義務対象領域と追加領域を統合した包括的患者ケア</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/social-health-needs-care-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:36:23-08:00</news:publication_date><news:title>Các nhu cầu xã hội liên quan đến sức khỏe trong các hệ thống y tế quy mô lớn</news:title></news:news></url>
<url><loc>https://news.medxy.ai/health-related-social-needs-in-a-large-health-system-integrating-cms-mandated-and-additional-domains-for-comprehensive-patient-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:36:04-08:00</news:publication_date><news:title>Health-Related Social Needs in a Large Health System: Integrating CMS-Mandated and Additional Domains for Comprehensive Patient Care</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/standardizing-all-residual-disease-assessment/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:35:13-08:00</news:publication_date><news:title>ALLの残存病変評価をどう標準化するか：2026年クロスエイジ・ガイドラインの重要提言</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/global-all-guidelines-2026/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:34:46-08:00</news:publication_date><news:title>Đồng thuận toàn cầu về đo lường bệnh tồn dư trong ALL: các khuyến nghị then chốt từ hướng dẫn liên tuổi 2026</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/all-residual-disease-detection/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:34:17-08:00</news:publication_date><news:title>统一 ALL 残留病灶检测：2026 跨年龄指南关键建议</news:title></news:news></url>
<url><loc>https://news.medxy.ai/global-consensus-residual-disease/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:33:53-08:00</news:publication_date><news:title>A Global Consensus for Measuring Residual Disease in ALL: Key Recommendations from the 2026 Cross‑Age Guideline</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/copd-inhaler-therapy-guidelines/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:32:50-08:00</news:publication_date><news:title>优化COPD管理：取消事前授权对不列颠哥伦比亚省指南一致性吸入治疗的影响</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/advancing-copd-treatment/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:32:34-08:00</news:publication_date><news:title>COPD治療を前進させる：ブリティッシュコロンビア州における事前承認撤廃がガイドライン適合吸入療法に与えた影響</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/improving-copd-care/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:32:12-08:00</news:publication_date><news:title>Cải thiện chăm sóc COPD: Tác động của việc bãi bỏ phê duyệt trước đối với thuốc hít phù hợp hướng dẫn tại British Columbia</news:title></news:news></url>
<url><loc>https://news.medxy.ai/enhancing-copd-care-impact-of-removing-prior-authorization-on-guideline-concordant-inhaled-therapies-in-british-columbia/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:31:57-08:00</news:publication_date><news:title>Enhancing COPD Care: Impact of Removing Prior Authorization on Guideline-Concordant Inhaled Therapies in British Columbia</news:title></news:news></url>
<url><loc>https://news.medxy.ai/precursor-lesions-exhibit-distinct-growth-patterns-after-atrophic-onset-in-age-related-macular-degeneration/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:31:18-08:00</news:publication_date><news:title>Precursor Lesions Exhibit Distinct Growth Patterns after Atrophic Onset in Age-Related Macular Degeneration</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/seasonal-postoperative-hypocalcemia/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:16:17-08:00</news:publication_date><news:title>春季为何更易出现术后低钙血症？全甲状腺切除术后的季节性影响新发现</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/seasonal-hypocalcemia-thyroidectomy/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:15:58-08:00</news:publication_date><news:title>甲状腺全摘術後低カルシウム血症にみる季節性の影響を読み解く</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/seasonal-hypocalcemia-thyroidectomy-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:15:33-08:00</news:publication_date><news:title>Giải mã ảnh hưởng theo mùa đối với hạ calci máu sau cắt toàn bộ tuyến giáp</news:title></news:news></url>
<url><loc>https://news.medxy.ai/unraveling-seasonal-influences-on-postoperative-hypocalcemia-after-total-thyroidectomy/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:15:16-08:00</news:publication_date><news:title>Unraveling Seasonal Influences on Postoperative Hypocalcemia After Total Thyroidectomy</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/tp53-surgery-decisions/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:14:35-08:00</news:publication_date><news:title>术前TP53突变如何影响甲状腺结节手术决策：三中心研究带来的新启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/preoperative-tp53-thyroid-nodules/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:14:18-08:00</news:publication_date><news:title>術前TP53変異で甲状腺結節の手術方針をどう見直すか：3施設共同研究からの示唆</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/refining-thyroid-surgery-decision/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:13:58-08:00</news:publication_date><news:title>Tinh chỉnh quyết định phẫu thuật đối với nhân tuyến giáp có đột biến TP53 trước mổ: Góc nhìn từ nghiên cứu ba trung tâm</news:title></news:news></url>
<url><loc>https://news.medxy.ai/refining-surgical-decisions-in-thyroid-nodules-with-preoperative-tp53-mutations-insights-from-a-tricenter-study/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:13:41-08:00</news:publication_date><news:title>Refining Surgical Decisions in Thyroid Nodules with Preoperative TP53 Mutations: Insights from a Tricenter Study</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/long-term-fibroid-outcomes/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:12:52-08:00</news:publication_date><news:title>子宫肌瘤保留子宫手术的长期结局：十年患者报告的再次治疗风险</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/long-term-fibroid-outcomes-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:12:33-08:00</news:publication_date><news:title>子宮温存術の長期転帰：子宮平滑筋腫に対する再治療リスクを10年追跡で検証</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/long-term-uterine-preservation-outcomes/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:12:06-08:00</news:publication_date><news:title>Kết cục dài hạn của các thủ thuật bảo tồn tử cung đối với u cơ trơn: nguy cơ điều trị lại do bệnh nhân báo cáo trong suốt một thập kỷ</news:title></news:news></url>
<url><loc>https://news.medxy.ai/long-term-outcomes-of-uterine-sparing-procedures-for-leiomyomata-a-decade-of-patient-reported-retreatment-risks/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:11:48-08:00</news:publication_date><news:title>Long-Term Outcomes of Uterine-Sparing Procedures for Leiomyomata: A Decade of Patient-Reported Retreatment Risks</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/alcoholic-hepatitis-inflammation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:11:04-08:00</news:publication_date><news:title>解读酒精相关肝炎：血清淀粉样蛋白A阳性肝细胞是肝脏炎症的核心介导者</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/alcoholic-hepatitis-inflammation-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:10:46-08:00</news:publication_date><news:title>アルコール関連肝炎を読み解く：serum amyloid A発現肝細胞が担う肝炎症の中核</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/alcohol-related-hepatitis-amyloid-a/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:10:27-08:00</news:publication_date><news:title>Giải mã viêm gan liên quan đến rượu: Tế bào gan biểu hiện serum amyloid A là trung gian trung tâm của viêm gan</news:title></news:news></url>
<url><loc>https://news.medxy.ai/decoding-alcohol-related-hepatitis-serum-amyloid-a-hepatocytes-as-central-mediators-of-liver-inflammation/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:10:10-08:00</news:publication_date><news:title>Decoding Alcohol-Related Hepatitis: Serum Amyloid A Hepatocytes as Central Mediators of Liver Inflammation</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/bepranemab-alzheimers-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:09:31-08:00</news:publication_date><news:title>Bepranemab 在前驱期至轻度阿尔茨海默病中的安全性、耐受性与疗效：来自 2 期随机对照试验的启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/bepranemab-alzheimers-trial-results/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:09:10-08:00</news:publication_date><news:title>前駆期から軽度アルツハイマー病におけるBepranemabの安全性・忍容性・有効性：第2相ランダム化比較試験からみた知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/bepranemab-alzheimers-trial-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:08:47-08:00</news:publication_date><news:title>Bepranemab trong Alzheimer giai đoạn tiền triệu chứng đến nhẹ: độ an toàn, khả năng dung nạp và hiệu quả qua một thử nghiệm ngẫu nhiên pha 2</news:title></news:news></url>
<url><loc>https://news.medxy.ai/safety-tolerability-and-efficacy-of-bepranemab-in-prodromal-to-mild-alzheimers-disease-insights-from-a-phase-2-randomized-controlled-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:08:28-08:00</news:publication_date><news:title>Safety, Tolerability, and Efficacy of Bepranemab in Prodromal-to-Mild Alzheimer&#8217;s Disease: Insights from a Phase 2 Randomized Controlled Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/primary-aldosteronism-diagnosis-6/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:07:20-08:00</news:publication_date><news:title>原发性醛固酮增多症诊断再推进：基于血清类固醇谱的无创分型与侧化识别</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/primary-aldosteronism-diagnosis-5/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:06:59-08:00</news:publication_date><news:title>原発性アルドステロン症の診断を前進させる：非侵襲的血清ステロイド解析による片側性判定とコルチゾール過剰の評価</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/primary-aldosteronism-diagnosis-4/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:06:36-08:00</news:publication_date><news:title>Nâng cao chẩn đoán cường aldosterone nguyên phát: Phân tích steroid huyết thanh không xâm lấn để xác định khu trú một bên và tăng cortisol</news:title></news:news></url>
<url><loc>https://news.medxy.ai/advancing-primary-aldosteronism-diagnosis-noninvasive-serum-steroid-profiling-for-lateralization-and-cortisol-excess/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:06:19-08:00</news:publication_date><news:title>Advancing Primary Aldosteronism Diagnosis: Noninvasive Serum Steroid Profiling for Lateralization and Cortisol Excess</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/eplontersen-cardiac-remodeling-5/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:05:40-08:00</news:publication_date><news:title>Eplontersen在多大程度上能抑制ATTR心肌病的心脏重构：来自CARDIO-TTRansform试验的结果</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/eplontersen-cardiac-remodeling-4/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:05:19-08:00</news:publication_date><news:title>eplontersenはATTR心筋症の心リモデリングをどこまで抑えるか：CARDIO-TTRansform試験からの示唆</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/eplontersen-cardiac-benefits/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:04:56-08:00</news:publication_date><news:title>Eplontersen: Lợi ích khiêm tốn trên tái cấu trúc tim trong amyloidosis transthyretin kèm bệnh cơ tim</news:title></news:news></url>
<url><loc>https://news.medxy.ai/eplontersen-cardiac-remodeling-6/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:04:35-08:00</news:publication_date><news:title>Eplontersen’s Modest Benefits on Cardiac Remodeling in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the CARDIO-TTRansform Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/cartilage-repair-enhancement/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:03:48-08:00</news:publication_date><news:title>绵羊模型中自体富血小板血浆富集软骨基质联合富生长因子血浆可增强软骨修复：基于 MOCART 2.0 MRI 评分的评估</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/cartilage-regeneration-mocart-2-0/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:03:02-08:00</news:publication_date><news:title>Tăng cường phục hồi sụn bằng ma trận sụn giàu huyết tương tiểu cầu tự thân trong mô hình cừu: Đánh giá theo thang điểm MRI MOCART 2.0</news:title></news:news></url>
<url><loc>https://news.medxy.ai/enhancement-of-cartilage-repair-using-autologous-platelet-rich-plasma-enriched-chondral-matrix-in-an-ovine-model-assessed-by-mocart-2-0-mri-scoring/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:02:46-08:00</news:publication_date><news:title>Enhancement of Cartilage Repair Using Autologous Platelet-Rich Plasma-Enriched Chondral Matrix in an Ovine Model Assessed by MOCART 2.0 MRI Scoring</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/monoshade-vs-multishade-resin/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:01:57-08:00</news:publication_date><news:title>非龋性颈部病损修复中单色与多色复合树脂的比较：一项36个月随机临床试验的启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/noncarious-cervical-lesions/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T02:01:35-08:00</news:publication_date><news:title>非う蝕性頸部病変における単色 vs マルチシェード・コンポジットレジン：36か月無作為化臨床試験からの知見</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/monochromatic-vs-polychromatic-composites/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T02:01:08-08:00</news:publication_date><news:title>So sánh nhựa composite đơn sắc và đa sắc trong tổn thương cổ răng không sâu răng: Góc nhìn từ thử nghiệm lâm sàng ngẫu nhiên 36 tháng</news:title></news:news></url>
<url><loc>https://news.medxy.ai/evaluating-single-shade-versus-multi-shade-composite-resins-in-non-carious-cervical-lesions-insights-from-a-36-month-randomized-clinical-trial/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:00:52-08:00</news:publication_date><news:title>Evaluating Single-Shade Versus Multi-Shade Composite Resins in Non-Carious Cervical Lesions: Insights from a 36-Month Randomized Clinical Trial</news:title></news:news></url>
<url><loc>https://news.medxy.ai/zh/il-6-inhibition-atherosclerotic-disease-3/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>zh</news:language></news:publication><news:publication_date>2026-11-20T02:00:12-08:00</news:publication_date><news:title>ziltivekimab对动脉粥样硬化性疾病的作用：临床试验证据与转化医学启示</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ja/il-6-inhibition-atherosclerotic-disease/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>ja</news:language></news:publication><news:publication_date>2026-11-20T01:59:50-08:00</news:publication_date><news:title>動脈硬化性疾患に対するシルチベキマブのIL-6阻害：臨床試験エビデンスとトランスレーショナルな示唆</news:title></news:news></url>
<url><loc>https://news.medxy.ai/vi/il-6-inhibition-atherosclerotic-disease-2/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>vi</news:language></news:publication><news:publication_date>2026-11-20T01:59:28-08:00</news:publication_date><news:title>Ức chế IL-6 bằng siltuximab trong các bệnh lý xơ vữa động mạch: Bằng chứng từ thử nghiệm lâm sàng và các gợi ý mang tính chuyển dịch</news:title></news:news></url>
<url><loc>https://news.medxy.ai/interleukin-6-inhibition-with-ziltivekimab-for-atherosclerotic-disease-clinical-trial-evidence-and-translational-insights/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T01:59:09-08:00</news:publication_date><news:title>Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease: Clinical Trial Evidence and Translational Insights</news:title></news:news></url>
<url><loc>https://news.medxy.ai/dnl343-in-amyotrophic-lateral-sclerosis-from-promising-biological-activity-to-disappointing-clinical-outcomes/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:44:00-08:00</news:publication_date><news:title>DNL343 in Amyotrophic Lateral Sclerosis: From Promising Biological Activity to Disappointing Clinical Outcomes</news:title></news:news></url>
<url><loc>https://news.medxy.ai/ollin-biosciences-playbook/</loc><news:news><news:publication><news:name>Medxy AI</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T15:38:00-08:00</news:publication_date><news:title>The Value of Ollin Biosciences’ Playbook: Capturing Early Innovation Before the Geographic Shift</news:title></news:news></url>
</urlset>
